-
METHODOLOGICAL AND STATISTICAL LEARNINGS FROM INITIAL JOINT CLINICAL ASSESSMENT REPORTS UNDER THE EU HTA REGULATION: CROSS-COMPANY PERSPECTIVES
Aug 11, 2026, 17:15 PM -
FIXED-DOSE SUBCUTANEOUS RITUXIMAB VERSUS BSA-ROUNDED IV BIOSIMILAR: A COST-CONSEQUENCE ANALYSIS OF AN AS-PRACTICED MIXED FORMULARY AT SSMC A TERTIARY ONCOLOGY CENTRE IN THE MIDDLE EAST
Aug 11, 2026, 17:15 PM -
ADAPTIVE HTA FOR GENE THERAPIES AND ORPHAN DRUGS IN MENA REGION: A REGIONAL EXPERT CONSENSUS ON SUSTAINABLE AND EQUITABLE ACCESS
Aug 11, 2026, 17:15 PM -
FROM NARRATIVE TO NUMBERS: A MEDICAL ANTHROPOLOGY MODEL FOR TRANSLATING PATIENT-BASED EVIDENCE INTO HTA-READY METRICS
Aug 11, 2026, 17:15 PM -
EQ-5D-5L UTILITIES AMONG ADULTS WITH MYOPIA-RELATED LONG-TERM COMPLICATIONS: RESULTS FROM A REAL-WORLD INTERNATIONAL EUROPEAN SURVEY
Aug 11, 2026, 17:15 PM -
SETTING THE BAR WITHOUT A NUMBER: HTA AND GUIDELINE EXPECTATIONS FOR AI IN SLRS
Aug 11, 2026, 17:15 PM -
ANTICIPATING THE VALUE- AND PRICE-DETERMINATION CHALLENGE OF GLP-1 RA INDICATION EXPANSION ACROSS HETEROGENEOUS THERAPEUTIC AREAS: LESSONS FROM PD-1/PD-L1 AND TNF-α INHIBITORS INDICATION EXPANSION
Aug 11, 2026, 17:15 PM -
KWIT: A DIGITAL APPROACH TO SUPPORT COPD SCREENING AND MONITORING - RESULTS FROM AN INNOVATIVE APPROACH IN FRANCE
Aug 11, 2026, 17:15 PM -
BARRIERS IN ACCESS TO MULTI-INDICATION MEDICINES DRIVING INEQUITABLE ACCESS ACROSS THERAPY AREAS
Aug 11, 2026, 17:15 PM -
REVERSING FINLAND'S LONG-TERM DECLINE IN INDUSTRY-SPONSORED CLINICAL TRIALS COULD ADD OVER €1 BILLION IN SOCIETAL VALUE BY 2030
Aug 11, 2026, 17:15 PM -
VARIATION IN CONCEPTUAL AND OPERATIONAL DEFINITIONS OF DEPRESSION IN REAL-WORLD RESEARCH
Aug 11, 2026, 17:15 PM -
BURDEN OF PREVENTABLE MEDICATION ERRORS IN SPAIN: CLINICAL AND ECONOMIC IMPACT, AND THE POTENTIAL OF HEALTH TECHNOLOGIES
Aug 11, 2026, 17:15 PM -
ESMO-MCBS: DO CURRENT CRITERIA UNDERVALUE CLINICAL BENEFIT IN POOR-PROGNOSIS POPULATIONS
Aug 11, 2026, 17:15 PM -
DECODING CLINICAL HEURISTICS IN EARLY ALZHEIMER'S DISEASE: NEUROLOGISTS' PREFERENCES AND TRADE-OFFS IN AMYLOID-TARGETING THERAPY INITIATION
Aug 11, 2026, 17:15 PM -
HIGH BURDEN OF DEPRESSION AND ANXIETY IN OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: INSIGHTS FROM GERMAN CLAIMS AND CLINICAL DATA
Aug 11, 2026, 17:15 PM -
COMPARATIVE EFFECTIVENESS OF GABAPENTIN ALONE AND MEMANTINE WITH GABAPENTIN IN DIABETIC NEUROPATHY PATIENTS: EVIDENCE TO SUPPORT CLINICAL DECISION-MAKING
Aug 11, 2026, 17:15 PM -
UPDATED COST-EFFECTIVENESS ANALYSIS OF EVOLOCUMAB IN PATIENTS WITH CLINICALLY EVIDENT ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
Aug 11, 2026, 17:15 PM -
TARGETED LITERATURE REVIEW TO DEVELOP DISEASE CONCEPTUAL MODEL OF IGG4-RD
Aug 11, 2026, 17:15 PM -
A HARMONIZED APPROACH TO MENTAL HEALTH REFERENCE UNIT COST DEVELOPMENT USING PROVIDER-REPORTED PRIMARY DATA: EVIDENCE FROM THE STREAMLINE PROJECT
Aug 11, 2026, 17:15 PM -
WHY ASSESSORS ASK: ANTICIPATING AND MANAGING INFORMATION REQUESTS IN THE FIRST WAVE OF JCAS
Aug 11, 2026, 17:15 PM
